Previous 10 | Next 10 |
Massive trade on a binary event makes my month and helps eliminate much of my underperformance so far this year. Big buys on a couple of new stocks in June set my portfolio up for success as I consolidate my stocks down to more concentrated bets. A portfolio built for individual i...
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it will host a virtual R&D Day for investors and analysts on Wednesday, Sept. 29, 2021 at 8 a.m. CT. Horizon’s R&D Day will include presentations from the Company’s R&D leadership team and key opinion...
In February 2020, Horizon Therapeutics (NASDAQ: HZNP) launched what would become a successful drug in its arsenal of rare disease treatments: Tepezza, a treatment for thyroid eye disease. Little did Horizon know that the COVID-19 pandemic was about to rule almost every aspect of our...
The first patient has enrolled in Horizon Therapeutics' (HZNP) Phase 2 trial to evaluate HZN-7734 (formerly VIB7734), a fully human monoclonal antibody targeting immunoglobulin-like transcript 7 (ILT7), to treat people with moderate to severely active systemic lupus erythematosus ((SLE)).SLE ...
Horizon Therapeutics plc (Nasdaq: HZNP) today announced the first patient has enrolled in a Phase 2 trial to evaluate its development-stage medicine HZN-7734 (formerly VIB7734), a first-in-class, fully human monoclonal antibody targeting immunoglobulin-like transcript 7 (ILT7), to treat...
Devers to Share Inspiring Personal Story as Part of New Education Initiative and Podcast Series For Graves’ Disease Awareness Month in July, Horizon Therapeutics plc (Nasdaq: HZNP) is teaming up with world-renowned track star and three-time Olympic gold medalist Gail ...
Arrowhead Pharmaceuticals (ARWR) and Horizon Therapeutics (HZNP) announces a global collaboration and license agreement for ARO-XDH, a potential treatment for people with uncontrolled gout, for as much as $700M.Under the terms of the agreement, Arrowhead will receive $40M as an upfront paymen...
- Arrowhead to receive $40 million upfront payment - Horizon to receive a worldwide exclusive license for an investigational short interfering RNA (siRNA) therapeutic targeting xanthine dehydrogenase (XDH) Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) and Horizon Therapeutic...
-- Information to be featured in three oral presentations during the virtual conference -- Horizon Therapeutics plc (Nasdaq: HZNP) today announced the presentation of company information on Neuromyelitis Optica Spectrum Disorder (NMOSD) in three oral sessions during the 7th ...
Halvorsen's 13F portfolio value decreased from $36.37B to $33.58B. The number of positions decreased from 96 to 94. Viking Global added Bank of America while reducing JPMorgan Chase and dropping Walt Disney. The top three positions are Microsoft, BridgeBio Pharma, and Fidelity Nat...
News, Short Squeeze, Breakout and More Instantly...
Horizon Therapeutics Public Limited Company Company Name:
HZNP Stock Symbol:
NASDAQ Market:
Hitachi Construction Machinery Co. Ltd ADR (HTCMY) is expected to report for Q2 2024 DigitalBridge Group Inc. (DBRG) is expected to report $0 for Q3 2023 LY Corp ADR (YAHOY) is expected to report for Q2 2024 DT Midstream Inc. (DTM) is expected to report $0.9 for Q3 2023 Summit Mat...
Horizon Therapeutics Public Limited Company (HZNP) is expected to report $1.22 for Q3 2023
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION FOR IMMEDIATE RELEASE October 6, 2023 RECOM...